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A Frustrating Final Frontier in Lipid Management?*Peter Libby, MDS ince its discovery in 1963 by Kare Berg (1),multiple observational studies have impli-cated lipoprotein (a) [Lp(a)] in cardiovascular
risk. Lp(a) consists of a cholesterol-rich lipid particle
encircled by a modiﬁed apolipoprotein B and occa-
sionally studded with other apolipoproteins. The
Lp(a) particle contains an apolipoprotein B that has
undergone covalent linkage to the deﬁning apolipo-
protein, apo(a). Unlike low-density lipoprotein
(LDL) cholesterol, which follows a roughly Gaussian
distribution in the population, Lp(a) levels skew,
with most individuals in a lower range and a tail of
individuals that display higher Lp(a) concentrations
and corresponding elevated cardiovascular risk.
Heritability and ethnicity strongly inﬂuence Lp(a)
plasma concentrations. In particular, African
Americans tend to have higher Lp(a) levels than
Caucasians.
The discovery that apolipoprotein (a) [apo(a)] has
homology with plasminogen, an important enzyme in
ﬁbrinolysis, provided a potential connection between
Lp(a) and thrombosis (2). As apo(a) appears to lack the
enzymatic activity of plasminogen, some postulated
that it may serve as a “dominant negative” plasmin-
ogen interfering with thrombolysis. The functional
consequences of Lp(a) for thrombosis and thrombol-
ysis remain elusive, however. The study of the
mechanisms by which Lp(a) may exert its noxious
effects remains fragmentary and controversial. A
barrier to unraveling this important problem is the
species speciﬁcity of Lp(a), a protein that is not*Editorials published in JACC: Basic to Translational Science reﬂect the
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Amgen, Sanoﬁ-Regeneron, and Ionis Pharmaceuticals.present in the animals commonly used in studies of
experimental atherosclerosis. The heterogeneity of
Lp(a) presents another complexity. The apolipopro-
tein can contain a variable number of repeats of
“kringle”-like motifs, notably Kringle 4. The more
Kringle 4 repeats, the lower the plasma concentration
of the apolipoprotein. This heterogeneity in Lp(a)
isoforms and other issues render it a difﬁcult analyte.
These challenges to the standardized measurement of
Lp(a) concentrations have also hampered clinical
studies. The high heritability of Lp(a) concentrations
suggests a strong genetic component to an in-
dividual’s Lp(a) status. Despite all of these quanda-
ries encountered at the protein level and mysteries
regarding the mechanisms of Lp(a)’s adverse effects
on cardiovascular outcomes, strong human genetic
and epidemiological data support a causal role of
Lp(a) in arteriosclerotic cardiovascular disease (3–5),
and furnish one of the best substantiated genetic
links to aortic stenosis that have emerged from
genome-wide association studies (6).
Despite this conjunction of observational epide-
miology and genetic data, the therapeutic targeting of
Lp(a) has proven frustrating. The usual menu of drugs
that target lipid metabolism have little effect on
Lp(a), save for niacin. Unfortunately, nicotinic acid’s
beneﬁt for CAD patients has recently come into
question on the basis of results of recent outcome
trials (7,8).
The antibodies that neutralize proprotein con-
vertase subtilisin/kexin type 9 (PCSK9), currently
under investigation as LDL-lowering agents, offer a
glimmer of hope in this otherwise bleak preventive
perspective. Studies that have monitored lipoprotein
proﬁles in patients treated with these agents repro-
ducibly and consistently show reductions in Lp(a)
(9,10). We eagerly await the results of the large
outcome trials that are currently underway with 3
agents of this class. Perhaps these studies will enroll
enough individuals with higher categories of Lp(a) to
FIGURE 1 PCSK9 Modulates LDL and Lp(a) Concentrations by Distinct Mechanisms
This diagram depicts a human hepatocyte. (Bottom) The low-density lipoprotein receptor (LDL-R) cycle portrays the well-known effect of
proprotein convertase subtilisin/kexin type 9 (PCSK9) in targeting the LDL-R for lysosomal degradation to amino acids (a.a.), increasing its
catabolism and decreasing its recycling into the cell surface membrane. The reduced LDL-R numbers on the hepatocyte surface impede
low-density lipoprotein (LDL) clearance and hence raise its plasma levels. (Top) The action of PCSK9 to increase apolipoprotein (a) [apo(a)]
protein production by the hepatocyte, by a transcriptional or other mechanism that remains undeﬁned (black box). Increased production of
apo(a) by the hepatocyte increases the plasma concentration of the atherogenic lipoprotein (a) [Lp(a)] particles. Thus, anti-PCSK9 anti-
bodies lower LDL and Lp(a) concentrations by distinct mechanisms. The in vitro experiments presented by Villard et al. (12) in the
accompanying paper indicate that Lp(a) catabolism does not depend on the LDL receptor under the conditions of their experiments.
mRNA ¼ messenger ribonucleic acid.
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429permit subgroup analyses of sufﬁcient power to test
whether the anti-PCSK9 antibodies can improve out-
comes in individuals with augmented risk due to
higher concentrations of Lp(a). We might then at last
with these new line of agents have an evidence-basedtherapy to offer to our patients and families with
elevated risk of premature arteriosclerotic cardio-
vascular disease. Antisense oligonucleotide strategies
(ASO) for inhibiting apo(a) synthesis also show
promise as a novel therapeutic approach to lower
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430plasma Lp(a) levels (11). Yet the anti-PCSK9 anti-
bodies and antisense oligonucleotide strategy agents
require parenteral administration and entail consid-
erable expense. Hence, understanding the mecha-
nisms by which anti-PCSK9 antibodies reduce Lp(a)
might provide insight that could lead to a more
speciﬁc approach to lowering levels of this highly
atherogenic lipoprotein.SEE PAGE 419The study by Villard et al. (12) in this issue of
JACC: Basic to Translational Science offers a step in
this direction. The investigators studied skin ﬁbro-
blasts from normal individuals and from patients
with heterozygous or homozygous familial hyper-
cholesterolemia, a disease caused by defective
function of the LDL receptor. They also studied pri-
mary cultures of human hepatocytes. Their experi-
ments showed that uptake of Lp(a) by these various
cell types did not depend on the LDL receptor
(Figure 1). The results further demonstrated that
neither PCSK9 nor the anti-PCSK9 antibody alir-
ocumab inﬂuenced the internalization of Lp(a) by
these cells. As expected, statin treatment elevated
LDL receptor expression and increased the internal-
ization of LDL, whereas the addition of exogenous
recombinant PCSK9 reduced LDL receptor expression
and inhibited uptake of LDL. These observations
provided a “control” for the negative studies that
evaluated Lp(a) uptake. The ﬁndings of this study
indicate that anti-PCSK9 antibodies do not alter the
catabolism of Lp(a) as a mechanism to explain their
reduction in this particle.
Further studies in liver cells showed that treat-
ment with PCSK9 increased the release of apo(a) from
human hepatocytes by 3-fold (Figure 1). Addition of
the anti-PCSK9 antibody reversed the substantial in-
crease in Lp(a) secretion provoked by PCSK9. These
results offer several novel ﬁndings. Lp(a) uptake does
not appear to depend on the classical LDL receptor.
PCSK9 does not alter the binding or uptake of Lp(a)by “peripheral” cells exempliﬁed by dermal ﬁbro-
blasts. Finally, the observations in primary human
hepatocytes show that PCSK9 directly augments
Lp(a) production (Figure 1). The mechanism by which
PCSK9 produces this augmented protein production
remains unknown, but it should prove tractable to
further analysis using the in vitro approach adopted
in this study. Yet the phenomenon reported by
Villard et al. (12) provides a ﬁrst step in understand-
ing why anti-PCSK9 antibodies lower levels of Lp(a)
in patients.
The ﬁnding that anti-PCSK9 can inhibit hepatocyte
production of apo(a) indicates that other agents
might modulate this process, including small mole-
cules that might be orally available and less costly to
produce than biologics or antisense strategies. It is
unclear to what extent PCSK9’s elevation in Lp(a)
production results from regulation of transcription,
translation, or altered intracellular proteolysis. Yet
the study by Villard et al. (12) raises the optimistic
note that further dissection of the molecular mecha-
nisms by which PCSK9 modulates Lp(a) production
will not only increase our understanding of the ef-
fects of this pleiotropic molecule but also provide
potential new areas of development for therapies that
can modulate Lp(a). Given the dearth of acceptable
pharmacological approaches to lowering Lp(a) in our
current armamentarium, the advent of the anti-
PCSK9 antibodies and the new insight that they
lower Lp(a) plasma concentrations by inhibiting he-
patic production rather than by augmenting catabo-
lism, as they do in the case of LDL, has both
mechanistic and therapeutic implications for the
future.
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